Insider filing · NAMS

Forbion IV Management B.V. sold $2.3M of NewAmsterdam Pharma (NAMS)

Executed Dec 20 2024, disclosed Dec 26 2024, 6 days later, against a two-business-day limit.

Returns are measured on stock purchases only.

FV Forbion IV Management B.V. 10% owner profile →

Forbion IV Management B.V. (10% owner) filed 3 Form 4 reports as a reporting entity in the past 24 months (0 purchases, 3 sales, 1 filed past the two-business-day deadline), most often in NewAmsterdam Pharma Company N.V. (NAMS). The largest single filing was $4.9M of NAMS (191,762 sh across 3 lots, as filed), executed Dec 12 2024.

NAMS NewAmsterdam Pharma Company N.V. NAMS · Healthcare · 45 filings in 24 months ticker →

Healthcare · NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with ca…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→